期刊
CANCER LETTERS
卷 447, 期 -, 页码 48-55出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2019.01.017
关键词
CRISPR-Cas9; Cancer; Gene editing; Immunotherapy; Oncolytic virotherapy
类别
资金
- National Natural Science Foundation of China [81803778]
- Key Research and development Project of Zhejiang Province [2018C0302]
- Medical and Health Care Key Project of Zhejiang Province [WKJ-ZJ-1629]
- Public Welfare Project of Zhejiang Province [2016C37101, 2017C33216, LGF18H160035]
- High-level Talent Project of Lishui City [2014RC01]
- Science and Technology Development Project of Lishui City [2017ZDXK07]
- Analysis Test Project of Zhejiang Province [2018C37039]
Cancer is a genetic disease stemming from cumulative genetic/epigenetic aberrations. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9-mediated genome editing technology has been extensively applied in various cell types and organisms, both in vitro and in vivo, for efficient gene disruption and gene modification. CRISPR-Cas9 has shown great promise for the treatment of cancer. However, despite its advantages and tremendous potential, numerous challenges, such as fitness of edited cells, editing efficiency, delivery methods and potential off-target effects, remain to be solved for completely clinical application. Here, we present the potential applications and recent advances of CRISPR-Cas9 in cancer therapy, and discuss the challenges that might be encountered in clinical applications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据